Loading
journalsJournal
Journal of experimental & clinical cancer research
An Italian-rooted open access journal for bench-to-bedside cancer research, from tumour models to early clinical studies. Read by translational cancer biologists and clinician scientists.
Also called: Journal of experimental & clinical cancer research : CRJ Exp Clin Cancer ResJECCR
Overview
The Journal of Experimental & Clinical Cancer Research describes itself as an online peer-reviewed journal publishing original research papers, reviews and commentaries in cancer research from bench to bedside, seeking to bridge laboratory discoveries with the understanding, prevention, diagnosis and treatment of cancer. It is the official journal of the Regina Elena National Cancer Institute in Rome and is owned by the Association for the Promotion of International Tumor Studies; it is published by BMC, part of Springer Nature. Submissions are expected to report findings not previously published in the same model, studies performed in multiple cell lines, and conclusions that go beyond incremental results. NLM catalogues it from 1982 and notes that print issues ceased with volume 26 in 2007. The Directory of Open Access Journals lists it as fully open access since 2008 with anonymous peer review, an article processing charge, and CC BY and CC0 licences.
Publisher
BMC (Springer Nature) · Regina Elena National Cancer Institute
Scope
translational cancer research
Website
Access model
open access
Founded
1982
ISSN
0392-9078
observational202319 citations
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
This is the paper Europe PMC returns for registry id NCT03476681 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
review2019752 citations
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
One of the most cited reviews Europe PMC returns for CTLA-4 in Colorectal cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Antonio Rosato
Scientific Director
Tumour immunologyCancer immunotherapyTranslational research
Immunologist and Scientific Director of the Istituto Oncologico Veneto, leading its translational cancer research.
Christian Singer
Vice-President
Breast cancerGynaecological oncologyHereditary cancer
Gynaecological oncologist at the Medical University of Vienna and ABCSG Vice-President, known for work on breast cancer and hereditary cancer risk.
Fan Daiming
President (理事长) of the China Anti-Cancer Association
Integrative oncologyProfessional society leadershipCancer control policy
Academician who presides over the China Anti-Cancer Association, China's national oncology society with branches in every province and around 260,000 individual members.
Giovanni Blandino
Scientific Director, IRCCS Regina Elena National Cancer Institute
Mutant p53 biologyTranslational oncologyCancer metabolism
Molecular oncologist known for mutant p53 research, appointed Scientific Director of Rome's Regina Elena National Cancer Institute in 2026.
Michael von Bergwelt
Director, Department of Medicine III (Hematology and Oncology), LMU Munich
HaematologyCell therapyImmunotherapy toxicity
Michael von Bergwelt is a haematologist who leads LMU's cell therapy and immuno-oncology programme.
Michał Mikula
Deputy Director for Scientific Affairs
Cancer geneticsColorectal cancerTranslational research
Molecular geneticist who leads the scientific programme of Poland's National Research Institute of Oncology.
Yu Jinming
President (院长), Shandong Cancer Hospital and Institute
Radiation oncologyHospital managementCancer research
Academician of the Chinese Academy of Engineering who is President of Shandong Cancer Hospital and Institute, the provincial cancer hospital in Jinan.
observationalJournal of experimental & clinical cancer research 202319 citations
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
This is the paper Europe PMC returns for registry id NCT03476681 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
reviewJournal of experimental & clinical cancer research 2019752 citations
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
One of the most cited reviews Europe PMC returns for CTLA-4 in Colorectal cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Similar pages
- JournalCancer letters
Shares Fan Daiming, PubMed & Europe PMC.
- JournalCancer treatment reviews
Shares Yu Jinming, PubMed & Europe PMC.
- JournalJournal of hematology & oncology
Shares Yu Jinming, PubMed & Europe PMC.
- JournalInternational journal of cancer
Shares Fan Daiming, PubMed & Europe PMC.